Key clinical point: Guadecitabine produced responses in certain patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who failed azacitidine.
Major finding: Eight patients (14.3%) responded, and the median duration of response was 11.5 months.
Study details: A phase 2 trial of 56 patients with high-risk MDS or low-blast-count AML.
Disclosures: The trial was sponsored by Groupe Francophone des Myelodysplasies in collaboration with Astex Pharmaceuticals. The researchers reported having no competing interests.
Sébert M et al. Haematologica. 2019 Feb 7. doi: 10.3324/haematol.2018.207118.